Contribute Try STAT+ Today

After protracted criticism over its pricing for a game-changing tuberculosis medicine, Johnson & Johnson (JNJ) is lowering the price as part of a larger incentive scheme designed to increase usage in dozens of low and middle-income countries, but the effort was met with a mixed reaction.

The health care giant is dropping the price for Sirturo by 15%, from $400 to $340 for a six-month treatment course, for more than 130 countries that are eligible to purchase the tablet through the STOP TB Partnership, a collective created by the United Nations that administers a global fund for distributing TB drugs. However, the cost could drop still more depending upon quantities that are purchased.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.